The extensive team at Slaughter and May addresses a variety of contentious and non-contentious matters, including commercial agreements, IP rights strategies and M&A. Duncan Blaikie and Claire Jackson jointly oversee matters. Blaikie frequently guides clients through the complexities of licensing, collaboration, and research and development agreements, while Jackson handles transactional demergers, joint ventures and inter-conditional asset swaps. IP licensing arrangements are a practice strength of Laura Houston.
Legal 500 Editorial commentary
Key clients
- GlaxoSmithKline
- Hikma
- Thermo Fisher
- Novo Nordisk
- Bupa
- GE Healthcare
- Union Medical
- Reckitt Benckiser
- Immunocore
- Oxford Nanopore
- Lonza
- CSL
- Enara Bio
- Artha Health Limited
- International Finance Facility For Immunisation Company
- Mylan
- Illumina
- Cantel Medical Corp
- Varian Medical Systems
- Oxford Sciences Enterprises
- Bunzl
- Afreximbank
- Takeda
- Shire Pharmaceuticals
- Virgin Active
- Deepmind
- The Royal Marsden Cancer Charity
- Orchard Therapeutics plc
- AOP Health International Management AG
- ELIQUENT Life Sciences
- Covis Pharma
- GHO Capital
Work highlights
- Handled ELIQUENT Life Sciences and GHO Capital Partners LLP on ELIQUENT’s acquisition of RApport Global Strategic Services.
- Advised the Royal Marsden Cancer Charity (the charity which raises money to support The Royal Marsden on the brand-related aspects of its partnership arrangements with the Ralph Lauren brand.
Lawyers
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
The lawyer(s) leading their teams.
Duncan Blaikie, Claire Jackson